Emerging research suggest this peptide, a dual activator targeting both the gut-brain axis and GIP , could offer a promising advancement for obesity treatment. Early clinical trials have shown considerable losses in visceral tissue, possibly outperforming existing body composition therapies . However , additional evaluation is necessary to fully as